We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

Growing up with an OB-GYN father, Rachel Blank assumed that most women received excellent gynecological care. In 2024, Allara ...

Duaa Eldeib, Maya Miller, Annie Waldman and Max Blau ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The U.S.

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

Elevance Health's financial outlook for FY 2025 anticipates GAAP diluted earnings per share (EPS) to be in the range of $30.40 to $31.10 and adjusted diluted EPS to be in the range of $34.15 to $34.85 ...

Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for The Cigna Group in a report issued on Tuesday, ...

Buying $1000 In CI: If an investor had bought $1000 of CI stock 20 years ago, it would be worth $11,032.06 today based on a ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a look at where The Cigna Group (NYSE:CI) stands against the other large-cap ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

This was the stock's second consecutive day of gains.